Olezarsen Sodium
Brand Names: Tryngolza
Methodology & AI Transparency ⓘ
Olezarsen Sodium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 80 mg/.8mL Injection, Solution and 50 mg/.8mL Injection, Solution and manufactured/labeled by Ionis Pharmaceuticals, Inc.
- 2 Real-world patient consensus: 91% patient "Worth It" rating across 19 anonymous logs for Olezarsen Sodium (RxNorm RXN-71860101-3047).
- 3 Typical cash cost range: 30-day cash pricing ranges from $137.29 discount cash to $336.36 walk-in retail (NADAC $3.1800/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Olezarsen Sodium include nausea (8.9%), headache (8.4%), dizziness (6.8%).
Ask our AI Specialists anything about Olezarsen Sodium
Olezarsen Sodium Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 80 mg/.8mL Injection, Solution and 50 mg/.8mL Injection, Solution and manufactured/labeled by Ionis Pharmaceuticals, Inc. (NDC 71860-101, 71860-102), Olezarsen Sodium operates within subcutaneous-route apoc-iii-directed rna interaction treatment algorithms requiring prescription authorization.
Delivered via 80 mg/.8mL Injection, Solution and 50 mg/.8mL Injection, Solution (subcutaneous-route; NDC 71860-101, 71860-102), Olezarsen Sodium mediates apoc-iii-directed rna interaction physiological effects manufactured/labeled by Ionis Pharmaceuticals, Inc. with dose-dependent receptor occupancy and systemic clearance.
Clinical clearance of Olezarsen Sodium (APOC-III-directed RNA Interaction) relies on hepatic enzymatic processing and renal clearance proportional to creatinine clearance (olezarsen sodium) with a Biphasic clearance with 5–15 hr terminal t½ under Olezarsen Sodium maintenance half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Olezarsen Sodium (80 mg/.8mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after olezarsen sodium administration.
FDA clinical labeling for Olezarsen Sodium restricts administration in known hypersensitivity to olezarsen sodium or structurally related apoc-iii-directed rna interaction compounds; concomitant contra-labeled cyp/transporter therapies during active olezarsen sodium administration across 80 mg/.8mL Injection, Solution, 50 mg/.8mL Injection, Solution, with self-reported patient tracking dominated by nausea (8.9% of reports), headache (8.4% of reports), dizziness (6.8% of reports).
Avoid overlapping apoc-iii-directed rna interaction prescriptions alongside Olezarsen Sodium to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Olezarsen Sodium dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Olezarsen Sodium or structurally related apoc-iii-directed rna interaction compounds
- Concomitant contra-labeled CYP/transporter therapies during active Olezarsen Sodium administration
Logged Side-Effect Incidence (19 Reports)
Olezarsen Sodium Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Olezarsen Sodium)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with In adults with FCS, olezarsen significantly lowers apoC-III in all major lipoprotein pools, particularly in total apoB and apoA-I. Atherosclerosis • 2025-09-15 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 40706406 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient experience with familial chylomicronemia syndrome before and after Results of this qualitative study underscore the significant burden of FCS and support the effectiveness of olezarsen from the patient perspective. Journal of clinical lipidology • 2025-01-15 • Phase III Randomized Trial | N = 14 | 88/100 | PMID 40713231 ↗ |
Olezarsen Sodium Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.1800/unit (~$95.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $336.36 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $137.29 / mo | View logs ↓ |
Olezarsen Sodium Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Olezarsen Sodium RxNorm Concept ID | RXN-71860101-3047 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.1800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $336.36 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $137.29 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Olezarsen Sodium Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Olezarsen Sodium: FDA labeling (2026-07-01, NDC 71860-101), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Olezarsen Sodium community threads and patient logs by age, biological sex, dosage, and treatment duration.